4,770 Shares in Illumina, Inc. $ILMN Acquired by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 4,770 shares of the life sciences company’s stock, valued at approximately $626,000.

A number of other institutional investors have also recently modified their holdings of ILMN. Capital World Investors grew its holdings in shares of Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB raised its stake in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Illumina in the third quarter valued at about $61,663,000. Massachusetts Financial Services Co. MA bought a new stake in Illumina during the fourth quarter worth about $73,532,000. Finally, State Street Corp lifted its position in Illumina by 6.8% during the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.17% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $134.50 on Monday. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a twelve month low of $69.83 and a twelve month high of $155.53. The company has a market cap of $20.43 billion, a price-to-earnings ratio of 24.68, a price-to-earnings-growth ratio of 2.58 and a beta of 1.49. The business’s fifty day moving average is $123.81 and its 200 day moving average is $124.95.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the company posted $0.95 EPS. Illumina’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. JPMorgan Chase & Co. reduced their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Stifel Nicolaus lifted their price objective on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.